muscle spasticity

A global clinical trial has been launched to evaluate the oral therapy candidate BMS-986368 for treating spasticity — muscle stiffness and spasms — in people with multiple sclerosis (MS). The Phase 2 study (NCT06782490), called BALANCE-MSS-1, will enroll about 200 adults with MS who have experienced spasticity…

I don’t have a Napoleon complex in the sense of being small. My body still spans 6 feet, though that’s only when I’m lying down; I doubt I get anywhere near 5 feet tall while seated in my wheelchair. Saint Jane (my wife) is 5-foot-2, and I now look…

I’ve just received four intramuscular Botox injections in my right arm to relieve the muscle spasticity that comes with multiple sclerosis. (OK, it wasn’t actually Botox, but Dysport, or abobotulinumtoxinA, another medication derived from the botulinum toxin to block muscle contractions.) And “my right arm is going…

An estimated 85 percent of people with MS experience some type of spasticity due to the disease, according to a recent report (p/w) published in Multiple Sclerosis and Related Disorders. Why is that important? Because spasticity is behind many of the disease’s most debilitating physical, emotional and mental…

PathMaker Neurosystems and the Brain and Spine Institute (ICM) in Paris will collaborate on human clinical trials to secure CE Mark clearance for PathMaker’s MyoRegulator PM-2200, a noninvasive neurotherapy technology to treat conditions linked to neural pathway disruption, including multiple sclerosis (MS). CE Mark — which stands for “Conformité Européenne,” or European Conformity…

PathMaker Neurosystems is the winner of the Universal Biotech Innovation Prize 2016 for its innovative, non-invasive neurotherapy technologies to treat conditions linked to neural pathway disruption, including multiple sclerosis (MS). The selection was announced at Innovation Days, an international event honoring the best in the life sciences and held in Paris on Oct. 3–4. Launched in 2009 by a…

Flex Pharma, Inc., a biotechnology company focused on therapies for muscle cramps and spasms associated with neuromuscular conditions, recently announced that it will present new data on its therapeutic agent FLX-787 at the 2015 Annual Meeting of the Society for Neuroscience, currently taking place in Chicago (October 17–21).